Bone Therapeutics Collaborates on ALLOB in Asia

Bone Therapeutics signed an exclusive agreement with Link Health and Shenzhen Pregene Biopharma to support manufacture, clinical development and commercialization of ALLOB allogeneic, off-the-shelf, bone cell therapy in China, Taiwan, Singapore, South Korea and Thailand.

Bone Therapeutics can receive up to €55 million (~USD $65 million)...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us